Cargando…
The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance
Tuberculosis treatment requires months-long combination chemotherapy with multiple drugs, with shorter treatments leading to relapses. A major impediment to shortening treatment is that Mycobacterium tuberculosis becomes tolerant to the administered drugs, starting early after infection and within d...
Autores principales: | Lake, M. Alexandra, Adams, Kristin N., Nie, Feilin, Fowler, Elaine, Verma, Amit K., Dei, Silvia, Teodori, Elisabetta, Sherman, David R., Edelstein, Paul H., Spring, David R., Troll, Mark, Ramakrishnan, Lalita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614234/ https://www.ncbi.nlm.nih.gov/pubmed/36763530 http://dx.doi.org/10.1073/pnas.2215512120 |
Ejemplares similares
-
Potential impact of efflux pump genes in mediating rifampicin resistance in clinical isolates of Mycobacterium tuberculosis from India
por: Narang, Anshika, et al.
Publicado: (2019) -
Rifampicin-Mediated Metabolic Changes in Mycobacterium tuberculosis
por: Yelamanchi, Soujanya D., et al.
Publicado: (2022) -
Rifampicin-induced thrombocytopenia
por: Verma, Ajay Kumar, et al.
Publicado: (2010) -
Tobramycin-Linked Efflux Pump Inhibitor Conjugates Synergize Fluoroquinolones, Rifampicin and Fosfomycin against Multidrug-Resistant Pseudomonas aeruginosa
por: Yang, Xuan, et al.
Publicado: (2018) -
Dodecanoic acid & palmitic acid disarms rifampicin resistance by putatively targeting mycobacterial efflux pump Rv1218c
por: Nirmal, Christy Rosaline, et al.
Publicado: (2023)